MetaCap

Krystal Biotech Inc. (KRYS)

NASDAQ: KRYSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

308.89-6.93 (-2.19%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KRYS stock chart

Technical analysis

Key statistics

All statistics
52-week range
212.02 – 382.54
Day range
308.22 – 321.24
Volume / Avg
286.70K / 283.88K
Beta
—

52-week range

$212.02$382.54

KRYS stock today

Krystal Biotech (KRYS) closed at $308.89 on Nov 20, down 2.19% (-$6.93), versus the S&P 500's 3.70% decline. Shares are 19.3% below their 52-week high of $382.54, set on Jun 30, 2026 and 45.7% above the 52-week low of $212.02, in the middle of the past year's range. KRYS is up 25.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 45.7%.

At 42.0x trailing earnings, Krystal Biotech trades above the peer-group median of 26.6x. Its forward P/E of 33.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Krystal Biotech

Company profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Headquarters
Pittsburgh, PA
Employees
295
IPO year
2017

Financial highlights

Full financials

In fiscal 2025, Krystal Biotech generated $389.1 million in revenue, up 33.9% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $204.8 million (+129.7% year over year), for a net margin of 52.6% versus a median of 26.1% in the prior 5 years. Operating margin was 41.5%.

Krystal Biotech annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2021FY 2021
Revenue$389.13M$290.51M$50.70M$0$0
Growth+33.94%+473.02%———
Net income$204.83M$89.16M$10.93M$-139.97M$-69.57M
EPS (diluted)$6.84$3.00$0.39$-5.49$-3.13

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$388.22+25.68%

  • Strong buy 1
  • Buy 10
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $284.00High $474.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$2.05 vs $1.84
Surprise
+11.41%

KRYS news

All KRYS news

Krystal Biotech peers

Health Care sector
KRYS peer companies
CompanyPrice% ChgMarket capCompare
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs KRYS
KYMRKymera Therapeutics Inc.115.31-3.42%$9.84Bvs KRYS
QGENQiagen N.V.49.30-0.66%$10.18Bvs KRYS
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs KRYS
RGENRepligen Corporation163.81-3.81%$10.47Bvs KRYS
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs KRYS
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs KRYS
TECHBio-Techne Corp72.67-0.04%$11.42Bvs KRYS

Indexes, lists and sector

Krystal Biotech stock FAQ

What is Krystal Biotech's stock price today?

KRYS last traded at $308.89 as of Nov 20, 4:00 PM EST, down 2.19% on the day. Prices are delayed at least 15 minutes.

What is KRYS's P/E ratio?

KRYS trades at a trailing P/E ratio of 41.97 and a forward P/E of 33.47, compared with a median of 26.6 for its closest peers.

Who is Krystal Biotech's CEO?

Mr. Krish S. Krishnan M.B.A., M.S. is the chief executive officer of Krystal Biotech Inc., which has about 295 employees.

What is the KRYS 52-week high?

The 52-week high for KRYS is $382.54 and the 52-week low is $212.02. The stock is currently 19.3% below its high.

Compare KRYS